We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+40.5%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$47M
AUM Growth
-$538M
Cap. Flow
-$549M
Cap. Flow %
-1,168.39%
Top 10 Hldgs %
25.17%
Holding
313
New
6
Increased
35
Reduced
92
Closed
155

Top Buys

Rank Stock Value
1
FLIN icon
Franklin FTSE India ETF
FLIN
+$334K
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$332K
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$224K
4
PBYI icon
Puma Biotechnology
PBYI
+$217K
5
ARRY
Array Biopharma Inc
ARRY
+$217K

Top Sells

Rank Stock Value
1
MPLX icon
MPLX
MPLX
+$60.3M
2
EQM
EQM Midstream Partners, LP
EQM
+$58.3M
3
ET icon
Energy Transfer Partners
ET
+$49.7M
4
EPD icon
Enterprise Products Partners
EPD
+$41.7M
5
MMP
Magellan Midstream Partners, L.P.
MMP
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
2 Financials 0.73%
3 Communication Services 0.52%
4 Consumer Discretionary 0.46%
5 Materials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.25M 4.79%
19,751
+4,520
+30% +$332K
PBYI icon
2
Puma Biotechnology
PBYI
$425M
$1.29M 2.76%
33,378
+7,119
+27% +$217K
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$1.19M 2.54%
48,922
+10,443
+27% +$217K
RARE icon
4
Ultragenyx Pharmaceutical
RARE
$2.87B
$1.14M 2.42%
16,385
+3,235
+25% +$185K
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$380M
$1.02M 2.16%
10,634
+2,494
+31% +$224K
MNTA
6
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.01M 2.14%
69,315
+16,033
+30% +$205K
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$1M 2.13%
73,653
+16,226
+28% +$198K
INCY icon
8
Incyte
INCY
$23.2B
$990K 2.11%
11,513
+2,440
+27% +$199K
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.38B
$981K 2.09%
14,540
+3,009
+26% +$175K
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$36.4B
$959K 2.04%
10,262
+2,399
+31% +$201K
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.4B
$940K 2%
10,671
+2,386
+29% +$199K
IRWD icon
12
Ironwood Pharmaceuticals
IRWD
$652M
$931K 1.98%
82,160
+19,091
+30% +$213K
EXEL icon
13
Exelixis
EXEL
$14.2B
$867K 1.84%
36,441
+7,624
+26% +$174K
REGN icon
14
Regeneron Pharmaceuticals
REGN
$70.8B
$850K 1.81%
2,071
+480
+30% +$198K
UTHR icon
15
United Therapeutics
UTHR
$22.6B
$831K 1.77%
7,084
+1,548
+28% +$180K
HALO icon
16
Halozyme
HALO
$9.19B
$818K 1.74%
50,835
+10,900
+27% +$177K
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$123B
$814K 1.73%
4,427
+892
+25% +$165K
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$798K 1.7%
7,138
+1,578
+28% +$172K
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.5B
$736K 1.57%
8,285
+1,832
+28% +$170K
LGND icon
20
Ligand Pharmaceuticals
LGND
$6.01B
$692K 1.47%
8,821
+1,893
+27% +$143K
FLIN icon
21
Franklin FTSE India ETF
FLIN
$2.73B
$668K 1.42%
28,491
+15,153
+114% +$334K
TBPH icon
22
Theravance Biopharma
TBPH
$877M
$649K 1.38%
28,612
+6,169
+27% +$156K
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$644K 1.37%
404
+95
+31% +$171K
NITE
24
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$603K 1.28%
23,777
-3,500
-13% -$61.9K
QURE icon
25
uniQure
QURE
$2.81B
$569K 1.21%
9,543
-1,135
-11% -$50.7K
1
2 3 4 5

Similar funds

AMIM
Aull & Monroe Investment Management Mobile, Alabama $215M AUM 28.37% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $215M AUM 6.73% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
OC
Optima Capital Beaverton, Oregon $215M AUM 17.28% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return

Virtus ETF Advisers's Q1 2019 Portfolio in Review

As of Q1 2019, Virtus ETF Advisers held 313 positions worth $47M, down 92% from $585M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Virtus ETF Advisers withdrew a net $549M in Q1 2019, closing 155 positions and reducing 92 holdings. Its most notable exit was MPLX, an estimated $60.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 7.3% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Virtus ETF Advisers opened a new position in Meta Platforms (Facebook) worth $73K.

  • Virtus ETF Advisers's largest Q1 2019 buy was Meta Platforms (Facebook): 435 shares worth $73K.
  • Virtus ETF Advisers added most to Franklin FTSE India ETF in Q1 2019, an estimated $334K increase.
  • Virtus ETF Advisers's biggest Q1 2019 reduction was Marathon Petroleum, cutting an estimated $21.6M.
  • Virtus ETF Advisers fully exited MPLX in Q1 2019, selling an estimated $60.3M.
  • Virtus ETF Advisers's ten largest holdings make up 25% of its $47M portfolio in Q1 2019.
  • Virtus ETF Advisers opened 6 new positions and closed 155 in Q1 2019.
  • Virtus ETF Advisers's portfolio value fell 92% quarter-over-quarter to $47M.

Based on Virtus ETF Advisers's 13F filing for Q1 2019, filed 14 May 2019.